# Baricitinib Compared to Standard Therapy in Patients With COVID-19

> **NCT04393051** · PHASE2 · UNKNOWN · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 126 (estimated)

## Conditions studied

- Covid-19
- SARS-CoV 2
- SARS Pneumonia

## Interventions

- **DRUG:** Baricitinib Oral Tablet

## Key facts

- **NCT ID:** NCT04393051
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-20
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-07-30
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393051, "Baricitinib Compared to Standard Therapy in Patients With COVID-19". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04393051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*